Spyre Therapeutics, Inc. SYRE EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from Spyre Therapeutics, Inc.’s reported figures.
Based on trailing twelve months.
The official record: Spyre Therapeutics, Inc.’s 10-Q, filed August 7, 2024, on SEC EDGAR. View the filing →
Ask your AI about Spyre Therapeutics, Inc.'s ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Spyre Therapeutics, Inc.'s EBITDA margin?
- Spyre Therapeutics, Inc. (SYRE) reported EBITDA margin of -17,462.5% in Q2 2023.
- How has Spyre Therapeutics, Inc.'s EBITDA margin changed year-over-year?
- Spyre Therapeutics, Inc.'s EBITDA margin decreased by 1327.5% year-over-year, from -1,223.3% to -17,462.5%.
- What does EBITDA margin mean?
- Operating cash profitability per sales dollar, before interest, taxes, and non-cash charges.
- How do you interpret EBITDA margin?
- Useful for comparing operating profitability across firms with different depreciation policies and leverage. High EBITDA margin alongside heavy capex can still mean weak free cash flow — pair it with FCF margin.
- How does EBITDA margin compare across companies?
- Widely used to compare capital-intensive businesses on a like-for-like basis. Less meaningful for banks and insurers.